Searchable abstracts of presentations at key conferences in endocrinology

ea0090p420 | Pituitary and Neuroendocrinology | ECE2023

Italian guidelines for the management of prolactinomas

Cozzi Renato , Simona Auriemma Renata , Pasquale De Menis Ernesto , Esposito Felice , Ferrante Emanuele , Iati Giuseppe , Mazzatenta Diego , Poggi Maurizio , Ruda Roberta , Tortora Fabio , Cruciani Fabio , Mitrova Zuzana , Saulle Rosella , Vecchi Simona , Basile Michele , Cappabianca Paolo , Paoletta Agostino , Papini Enrico , Persichetti Agnese , Samperi Irene , Scoppola Alessandro , Bozzao Alessandro , Caputo Marco , Doglietto Francesco , Ferrau Francesco , Lania Andrea , Laureti Stefano , Lello Stefano , Locatelli Davide , Maffei Pietro , Minniti Giuseppe , Peri Alessandro , Ruini Chiara , Settanni Fabio , Silvani Antonio , Veronese Nadia , Grimaldi Franco , Attanasio Roberto

Aim: This guideline (GL) is aimed at providing a reference for the management of prolactin (PRL)-secreting pituitary adenoma in non-pregnant adults.Methods: For each question, the panel identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices.Results: The present GL provides recommendations about the roles of pharmacological and neurosurgical treatment for the management of prolactinom...

ea0037ep75 | Adrenal cortex | ECE2015

Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing's disease persistent after pituitary surgery

Messina Erika , Albani Adriana , Ferrau Francesco , Trimarchi Francesco , Cannavo Salvatore

Pasireotide (SOM230) is a multireceptor ligand somatostatin analogue with high binding affinity to somatostatin receptor subtype 5, which is predominantly expressed in ACTH-secreting pituitary adenomas. It is indicated for the treatment of adult patients with Cushing’s disease (CD) for whom pituitary surgery is not an option or has not been curative. Our study evaluated the effects of pasireotide, administered for 12 months at a dose of 600–900 μg/daily, in five...

ea0063gp239 | Anterior and Posterior Pituitary | ECE2019

Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature

Giuffrida Giuseppe , Ferrau Francesco , Laudicella Riccardo , Cotta Oana Ruxandra , Vento Antonio , Baldari Sergio , Cannavo Salvatore

Background: Pituitary tumours (PT) are generally benign, but they can rarely show an aggressive behaviour, invade surrounding structures and/or grow/recur despite multimodal treatment, making their management extremely challenging. According to the latest guidelines, temozolomide (TMZ) can be an option after failure of standard therapies in aggressive PT, while little data are available on alternative approaches such as peptide receptor radionuclide therapy (PRRT). Herein we r...

ea0016p455 | Neuroendocrinology | ECE2008

Systemic comorbidities induce early vascular alterations in patients with active acromegaly

Ferrau Francesco , Romanello Giovanni , Squadrito Stefano , Carerj Scipione , Nipote Carmelo , Iudicello Raffaella , Trimarchi Francesco , Cannavo Salvatore

Mortality risk is increased in acromegalics, due to cerebrovascular and cardiovascular events. These events are namely related to atherosclerotic vascular alterations, both at coronary and peripheral level. Systemic comorbidities increase the risk of atherosclerosis, but the role of GH and IGF-1 excess is still debated. To evaluate the relationship between GH/IGF-1 excess, systemic atherogenic complications and vascular alterations we investigated stiffness index (β), pul...

ea0056p189 | Bone ' Osteoporosis | ECE2018

Novel heterozygous mutation of tissue-non-specific alkaline phosphatase (TNSALP) gene causing late-onset hypophosphatasia

Ruggeri Rosaria Maddalena , Certo Rosaria , Guarnieri Vito , Giovinazzo Salvatore , Ferrau Francesco , Cannavo Salvatore

Background: Hypophosphatasia (HPP) is a rare metabolic, inherited disease of bone metabolism, caused by loss-of-function mutations within the gene coding for TNSALP, that result in a decrease in serum ALP concentrations and consequent accumulation of ALP substrates outside of the cell, including inorganic pyrophosphate which inhibits bone mineralization. HPP leads to a variety of clinical manifestations across all ages and its prognosis is conditioned principally by the skelet...

ea0081ep702 | Pituitary and Neuroendocrinology | ECE2022

Giant pituitary adenomas in children and adolescents: clinical presentation, management and long-term outcome

Giuffrida Giuseppe , giovinazzo salvatore , Alessi Ylenia , Ragonese Marta , Cotta Oana Ruxandra , Angileri Filippo Flavio , Ferrau Francesco , Cannavo Salvatore

Background: Pituitary adenomas in children/adolescents represent around 3% of all intracranial neoplasms. They are more frequently hormone-secreting lesions, usually diagnosed in early childhood and late adolescence. Female gender is generally prevalent, because of most evident symptoms (i.e., irregular periods, galactorrhea, etc.). Giant pituitary adenomas (GA) very rarely occur in pediatric age, posing frequent challenges in their management.Patients a...

ea0063gp164 | Cushing's | ECE2019

Assessment of bone marrow fat by single-voxel vertebral magnetic resonance spectroscopy in cushing’s syndrome with or without vertebral fractures

Ferrau Francesco , Giovinazzo Salvatore , Tessitore Agostino , Messina Erika , Vinci Sergio , Mazziotti Gherardo , Lania Andrea , Longo Marcello , Granata Francesca , Cannavo Salvatore

Chronic hypercortisolism is associated with dramatic increase in fragility fractures. The evaluation of skeletal fragility in Cushing’s syndrome (CS) is a clinical challenge, since fractures may occur even in presence of normal bone mineral density (BMD). Recently, measurement of bone marrow fat (BMF) by vertebral magnetic resonance spectroscopy (MRS) was proposed as alternative tool for evaluating skeletal fragility in primary and secondary osteoporosis. Noteworthy, rece...

ea0092ps2-11-01 | Miscellaneous 2 | ETA2023

Temporal pattern of thyroid function changes in patients with cured and not cured adrenocorticotropin (ACTH)-Dependent Hypercortisolism

Paola Giuseppe , Alessi Ylenia , Giovinazzo Salvatore , Giuffrida Giuseppe , Casablanca Rosalinda , Ragonese Marta , Certo Rosaria , Ferrau Francesco , Cannavo Salvatore , Moleti Mariacarla

Context: Chronic hypercortisolism is known to impact the hypothalamus-pituitary-thyroid (HPT) axis, through a disruption of both thyrotropin-releasing-hormone and thyroid-stimulating hormone (TSH) release. These changes, in turn, are responsible for reduced triiodothyronine (T3) and thyroxine (T4) synthesis and secretion, eventually resulting in central hypothyroidism (C-Hypo). However, data on magnitude and timing of recovery of the above abnormalities are still controversial...

ea0081p531 | Adrenal and Cardiovascular Endocrinology | ECE2022

Long-term efficacy and safety of pasireotide in patients with Cushing’s disease: a monocentric experience

Alessi Ylenia , Luisa Torre Maria , Giovinazzo Salvatore , Giuffrida Giuseppe , Giandalia Annalisa , Casablanca Rosalinda , Flavio Angileri Filippo , Ragonese Marta , Ferrau Francesco , Cannavo Salvatore

Pasireotide is the first pituitary-directed approved therapy for Cushing’s disease (CD), effective in reducing UFC >50% in about half of patients, and with a good tolerability profile but associated with a relatively high incidence of hyperglicemia. The aim of this study was to evaluate efficacy and safety of long-term treatment with pasireotide (PAS) in patients with CD. Methods: We retrospectively evaluated 17 consecutive patients (11 females) with CD treated with P...

ea0081p396 | Pituitary and Neuroendocrinology | ECE2022

Precision medicine: new perspectives for the treatment of GH-secreting tumors - the miss study

Maria Berton Alessandro , Prencipe Nunzia , Bertero Luca , Corsico Marina , Cuboni Daniela , Baldi Marco , Bima Chiara , Bianchi Antonio , Mantovani Giovanna , Ferrau Francesco , SARTORATO PAOLA , Gagliardi Irene , Grottoli Silvia

Introduction: First-generation SRL (fg-SRL) represent the treatment of choice in acromegaly patients with post-neurosurgical adenomatous remnant and GH-hypersecretion. Anyway, approximately 60% of patients do not achieve adequate disease control. The main predictors of resistance include male sex, young age, invasiveness of the lesion and its hyperintensity on T2-weighted MRI scans; but also, SSTR2 expression, the cytokeratin pattern, Ki-67 and the presence of AIP gene mutatio...